Trial Profile
A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine; Epirubicin; Fluorouracil; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Apr 2022 Primary endpoint (pathologic complete response (pCR) rate) has been met, according to Results presented at the 113th Annual Meeting of the American Association for Cancer Research.
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
- 19 Nov 2021 Status changed from recruiting to completed.